 Home > Active Ingredient News > Study of Nervous System > Lancet Neurol: Is the oral brain penetrating BTK inhibitor tolebrtinib safe and effective in the treatment of relapsing multiple sclerosis?

Lancet Neurol: Is the oral brain penetrating BTK inhibitor tolebrtinib safe and effective in the treatment of relapsing multiple sclerosis?

 Last Update: 2021-11-01
 Source: Internet
 Author: User

Tags

lag 3 inhibitor

iodine test results

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Multiple sclerosis is an immune- mediated inflammatory demyelinating disease that causes loss of axons, neurological disease, and cumulative disability
.

Immunomodulatory treatment can lead to an annual recurrence rate as low as 0.

Immunity because existing treatments mainly affect peripheral adaptive immunity

Bruton tyrosine kinase is a non-receptor tyrosine kinase that is expressed in most hematopoietic cells (excluding T cells and fully differentiated plasma cells) and connects specific cell surface receptors to downstream signaling pathways , Which links immune stimulation with cell activation

Tolebritinib is an oral small molecule that irreversibly binds to Bruton's tyrosine kinase and inhibits its activity

The researchers conducted a 16-week phase 2b randomized, double-blind, placebo-controlled, cross-dose discovery trial in 40 centers (academic sites, specialist clinics, and general neurology centers) in 10 countries in Europe and North America
.

Eligible participants are adults aged 18-55 who have been diagnosed with relapsing multiple sclerosis (relapsing-remitting or relapsing secondary progressive multiple sclerosis) and meet one or more of the following Criteria: at least one relapse in the past year, at least two relapses in the past two years, or at least one active gadolinium-enhancing brain injury within 6 months before screening

Phase 2b randomized, double-blind, placebo-controlled, cross-dose discovery test diagnostic screening

From May 14, 2019 to January 2, 2020, a total of 130 participants were recruited and randomly assigned to take tolebrtinib: 33 to 5 mg, 32 to 15 mg, 33 to 30 mg and 32 to 60 mg
.

129 cases (99%) completed the treatment plan, and 126 cases entered the preliminary analysis

After 12 weeks of tolebrtinib treatment, new gadolinium-enhanced lesions were reduced in a dose-dependent manner, and the 60 mg dose was the most effective, and the drug was well tolerated

Literature source: Reich DS, Arnold DL, Vermersch P, et al.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Lancet Neurol.
2021;20(9):729-738.
doi:10.
1016/S1474-4422(21)00237-4 Reich DS, Arnold DL, Vermersch P, et al.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Lancet Neurol.
2021;20(9):729-738.
doi:10.
1016/S1474-4422(21)00237-4 in This message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.